Research article mammaprint versus endopredict: poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.
The endopredict test provides a risk score that is either low-risk or high-risk of breast cancer recurring as distant metastasis the mammaprint test is used to predict the risk of recurrence within 10 years after diagnosis of stage i or stage ii breast cancer that is hormone-receptor-positive or hormone-receptor-negative.
Full-text paper (pdf): mammaprint versus endopredict: poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer. Comparison of risk classification between endopredict and mammaprint in er-positive/her2-negative primary invasive breast cancer. The endopredict gene-expression assay in clinical practice - performance and impact on clinical decisions ca, usa) and mammaprint® (agendia bv, amsterdam, the netherlands it provides additional prognostic information to standard pathological factors including ki67 and improves risk classification from common clinical.
Pdf | purpose to compare the concordance in risk classification between the endopredict and the mammaprint scores obtained for the same cancer samples on 40 estrogen-receptor positive/her2.
Shivers s, clark l, esposito n, howard n, king j, acs g, et al direct comparison of risk classification between mammaprint®, oncotype dx® and mammostrat® assays in patients with early stage breast cancer [abstract.